Response and survival in acute myeloid leukemia patients not candidates to transplantation treated with azacitidine versus palliative treatment: a retrospective study

Medwave
Mauricio Sarmiento MaldonadoPablo Ramírez Villanueva

Abstract

Acute myeloid leukemia has a high mortality if untreated. Hematopoietic stem cell transplantation is the only curative treatment so far. Patients who are not eligible to receive a transplant can be treated with hypomethylating agents that have shown to improve disease-free and overall survival. Retrospective description of the clinical characteristics of patients suffering from advanced myelodysplastic syndrome and acute myeloid leukemia that were treated with a hypomethylating agent as well as its adverse effects and response to treatment. This report shows our experience in 38 patients with acute myeloid leukemia treated with azacitidine or palliative treatment. Azacitidine was able to prolong survival in 80% of patients with a high incidence of adverse effects and negative impact on quality of life. Most of the patients treated with palliative intent died in the first month after diagnosis. Azacitidine can prolong survival but with significant adverse effects. Untreated patients had a high early mortality.

References

Jan 1, 2014·American Journal of Hematology·Sylvain ThépotUNKNOWN Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguë

❮ Previous
Next ❯

Citations

Nov 9, 2018·Leukemia & Lymphoma·Chadi NabhanJonathan Karl Kish

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.